SNP biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer

OBJECTIVE: Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/mL and 0.5 pg/mL, respectively, after six months of adjuvant anastrozole therapy had a 3-fold risk of recurrence, we aimed to identify a SNP-based model that wou...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pharmacogenet Genomics
Autori principali: Ingle, James N., Kalari, Krishna R., Barman, Poulami, Shepherd, Lois E., Ellis, Matthew J., Goss, Paul E., Buzdar, Aman U., Robson, Mark E., Cairns, Junmei, Carlson, Erin E., Casey, Abraham Eyman, Hoskin, Tanya L., Goodnature, Barbara A., Haddad, Tufia C., Goetz, Matthew P., Weinshilboum, Richard M., Wang, Liewei
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655717/
https://ncbi.nlm.nih.gov/pubmed/32649577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000415
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi